Clinical Research, Pharma & Healthcare FinancingAN2 Therapeutics Shares Phase 3 EBO-301 Data and Future MilestonesBusiness WireMay 2, 2025August 1, 2025 by Business WireMay 2, 2025August 1, 20250112 EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced...
